Navigation Links
Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
Date:11/19/2008

HAYWARD, Calif., Nov. 19 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biotechnology company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today announced that it has closed the final tranche of its Series A financing. Frazier Healthcare Ventures and Alta Partners co-led the $16.7 million tranche, which also included existing investors Burrill & Company, Three Arch Partners, and Altitude Life Science Ventures. This financing completes the Series A round, bringing the total amount raised to date to over $51 million.

"This financing provides substantial funding for Arete as we look toward the initiation of our Phase II clinical trial in the first quarter of 2009 using AR9281 for the treatment of metabolic syndrome," said James Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "We appreciate our investors' continued commitment to the value of our s-EH inhibitor platform."

"In the last six months, Arete successfully completed a Phase I clinical trials' program for AR9281, expanded its executive management team and completed extensive preclinical studies of s-EH inhibitors," stated James Topper, M.D., Ph.D., Chairman of the Board of Arete Therapeutics and General Partner of Frazier Healthcare Ventures. "Arete's extensive proprietary position in s-EH inhibitors, together with its efficient, focused drug discovery and development organization, position the Company to address the growing healthcare epidemic of metabolic syndrome and identify new therapeutics for cardiovascular and inflammatory disease."

About Arete Therapeutics Inc.

Arete Therapeutics is a privately-held biotechnology company dedicated to the discovery and development of novel drugs to treat metabolic, inflammatory and cardiovascular disease. It is the world's leading company focused on s-EH (soluble epoxide hydrolase), an important enzyme for the metabolism of arachidonic acid that plays an essential role in metabolic, inflammatory and cardiovascular physiology. The Company was founded by Dr. Bruce Hammock, a Professor at the University of California, Davis, who discovered s-EH. For more information on Arete Therapeutics, please visit http://www.aretetherapeutics.com.


'/>"/>
SOURCE Arete Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arete Therapeutics Bolsters Management Team
2. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
3. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
4. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
5. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
9. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
10. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
11. Cell Therapeutics Net Loss Declines as Operating Expenses Decrease By 58% in Third Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With the ... trusted supplier in the weighing industry, to extending its expertise across the entire laboratory ... immunoassays, hybridizations and more, allowing for its customers to 'Do More' in ...
(Date:6/19/2017)... Ames, Iowa (PRWEB) , ... June 19, 2017 , ... ... and interplay among its cells and tissues by delivering pollen and nectar containing nutrients ... and the means to stay healthy. , Many recent indicators point to a decline ...
(Date:6/15/2017)... , ... June 15, 2017 , ... ... has secured a Series B round of financing in the amount of $6 ... of private investors participated in the round. , The Series B funding will ...
(Date:6/14/2017)... , ... June 14, 2017 , ... ... 8th to discuss the initiative steered by the executive search firm, “Building Value ... of the Board of Directors of Foundation Medicine, led an open discussion with ...
Breaking Biology Technology:
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
Breaking Biology News(10 mins):